Martin Auster
Stock Analyst at Raymond James
(3.92)
# 630
Out of 5,161 analysts
52
Total ratings
55.81%
Success rate
10.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Strong Buy | $40 | $22.98 | +74.06% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $26.45 | +43.69% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $67.98 | +4.44% | 2 | Oct 30, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $59.76 | +80.72% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $229.01 | +18.34% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $18.06 | +93.80% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $317.23 | +33.66% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $59.07 | +103.15% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $21.71 | +383.65% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $7.63 | +240.76% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $7.71 | +1,456.42% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $36.48 | +58.99% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $532.82 | -63.21% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $2.02 | +4,751.49% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $139.52 | -57.00% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $41.80 | +55.50% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $17.04 | +328.40% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $16.94 | +360.45% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.47 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.84 | +386.43% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $12.85 | +63.42% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $63.79 | -74.92% | 1 | May 7, 2020 |
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $22.98
Upside: +74.06%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $26.45
Upside: +43.69%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $67.98
Upside: +4.44%
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $59.76
Upside: +80.72%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $229.01
Upside: +18.34%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $18.06
Upside: +93.80%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $317.23
Upside: +33.66%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $59.07
Upside: +103.15%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $21.71
Upside: +383.65%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $7.63
Upside: +240.76%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $7.71
Upside: +1,456.42%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $36.48
Upside: +58.99%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $532.82
Upside: -63.21%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $2.02
Upside: +4,751.49%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $139.52
Upside: -57.00%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $41.80
Upside: +55.50%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $17.04
Upside: +328.40%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $16.94
Upside: +360.45%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.47
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.84
Upside: +386.43%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $12.85
Upside: +63.42%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $63.79
Upside: -74.92%